Skip to main content

MoneyWorks4Me

Nectar Lifesciences informs about statements of investor complaints

04 Jan 2018 Evaluate

Pursuant to Regulation 13(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Nectar Lifesciences has informed about the Statement of Investor Complaints for the Quarter ended December 31, 2017.

The above information is a part of company’s filings submitted to BSE.

 

Peers
Company Name CMP
Sun Pharma. Inds. 1768.00
Dr. Reddys Labs. 1340.25
Cipla 1382.00
Lupin 1996.55
Zydus Lifesciences 1239.95
View more..